This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Abacavir and lamivudine

Read time: 1 mins
Marketing start date: 18 Nov 2024
...
 

Summary of product characteristics


Effective Time

20230927

Version

6

Spl Product Data Elements

Abacavir and lamivudine Abacavir and lamivudine ABACAVIR SULFATE ABACAVIR LAMIVUDINE LAMIVUDINE CELLULOSE, MICROCRYSTALLINE CROSCARMELLOSE SODIUM D&C YELLOW NO. 10 FD&C RED NO. 40 FERRIC OXIDE YELLOW HYPROMELLOSES MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED POLYSORBATE 80 POVIDONE K30 TITANIUM DIOXIDE LIGHT YELLOW TO YELLOW CAPSULE 1049

Application Number

ANDA208990

Brand Name

Abacavir and lamivudine

Generic Name

Abacavir and lamivudine

Product Ndc

70771-1053

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1053-9 Abacavir and Lamivudine Tablets, 600 mg/300 mg 90 Tablets Rx only Abacavir Sulfate and Lamivudine Tablet: Warning Card abacavir sulfate and lamivudine tablet abacavir sulfate and lamivudine tablet

Spl Medguide

SPL MEDGUIDE

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.